Effects of Evolocumab on the Postprandial Kinetics of Apo (Apolipoprotein) B100- and B48-Containing Lipoproteins in Subjects With Type 2 Diabetes - Taskinen, Marja-Riitta; Björnson, Elias; Kahri, Juhani; Söderlund, Sanni; Matikainen, Niina; Porthan, Kimmo; Ainola, Mari; Hakkarainen, Antti; Lundbom, Nina; Fermanelli, Valentina; Fuchs, Johannes; Thorsell, Annika; et al. (Arteriosclerosis, thrombosis, and vascular biology, 2021)
Keywords: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Anticholesteremic Agents - adverse effects; Anticholesteremic Agents - therapeutic use; Apolipoprotein B-100 - blood; Apolipoprotein B-48 - blood; Biomarkers - blood; Cholesterol - blood; Cholesterol, LDL - blood; Cholesterol, VLDL - blood; Chylomicron Remnants - blood; Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - diagnosis; Diabetes Mellitus, Type 2 - drug therapy; Dietary Fats - administration & dosage; Dietary Fats - blood; Dyslipidemias - blood; Dyslipidemias - diagnosis; Dyslipidemias - drug therapy; Endocrinology and Diabetes; Endokrinologi och diabetes; Female; Humans; Kinetics; Lipoproteins - blood; Lipoproteins, VLDL - blood; Male; Middle Aged; PCSK9 Inhibitors; Postprandial Period; Proprotein Convertase 9 - metabolism; Serine Proteinase Inhibitors - adverse effects; Serine Proteinase Inhibitors - therapeutic use; Time Factors; Treatment Outcome; Triglycerides - blood; Young Adult; apolipoprotein; cardiovascular diseases; kinetics; chylomicrons; evolocumab